This Week’s CGT News: CAR-T Breaks New Ground in Alzheimer’s
First CAR-T approach for Alzheimer’s reduces amyloid plaques in mice, while cell and gene therapies advance across blood cancers, retinal disease, amyloidosis, and FSHD
Clinical Scorecard: This Week’s CGT News: CAR-T Breaks New Ground in Alzheimer’s
At a Glance
Category Detail
Condition Alzheimer's Disease Key Mechanisms Engineered CAR-T cells targeting amyloid proteins Target Population Patients with Alzheimer's Disease Care Setting Research and clinical trials
Key Highlights
CAR-T cells reduced amyloid plaques in mouse models of Alzheimer's. Stem cell memory CAR-T cells show promise in relapsed/refractory CD19+ B-cell malignancies. Dual-targeting CAR-T therapy achieves complete responses in multiple myeloma and POEMS syndrome. OpRegen therapy shows durable vision gains in geographic atrophy. Optogenetic gene therapy restores light perception in advanced retinitis pigmentosa. Guideline-Based Recommendations
Diagnosis
Utilize imaging and biomarkers to assess amyloid plaque levels. Management
Consider CAR-T cell therapy for targeted amyloid clearance. Monitoring & Follow-up
Monitor for markers of brain-tissue inflammation post-therapy. Risks
Potential for cytokine release syndrome and other adverse effects. Patient & Prescribing Data
Patients with Alzheimer's and other neurodegenerative diseases.
CAR-T therapy may provide a novel approach to clear pathological proteins and support brain repair.
Clinical Best Practices
Conduct thorough patient assessments before CAR-T therapy. Monitor patients closely for adverse effects post-infusion. Engage in multidisciplinary discussions for optimal patient management. Related Resources & Content
